Although the treatment of myocardial infarction (MI) has improved considerably, it is still a
worldwide disease with high morbidity and high mortality. Whilst there is still a long way to …

This paper aims to provide an important update on the recent preclinical and clinical trials
using cell therapy strategies and engineered heart tissues for the treatment of postinfarction …

In the past decades, numerous preclinical studies and several clinical trials have evidenced
the feasibility of cell transplantation in treating heart diseases. Over the years, different …

Cardiovascular diseases (CVDs) are pointed out by the World Health Organization (WHO)
as the leading cause of death, contributing to a significant and growing global health and …

Myocardial infarction is the first cause of worldwide mortality, with an increasing incidence
also reported in developing countries. Over the past decades, preclinical research and …

Background In recent years, cardiovascular disease in particular myocardial infarction (MI)
has become the predominant cause of human disability and mortality in the clinical setting …

Heart failure secondary to cardiomyocyte loss and/or dysfunction is the number one killer
worldwide. The field of myocardial regeneration with its far-reaching primary goal of cardiac …

The investment of nearly 2 decades of clinical investigation into cardiac cell therapy has yet
to change cardiovascular practice. Recent insights into the mechanism of cardiac …

Aims Patients suffering from chronic ischaemic heart failure with reduced left ventricular
ejection fraction (HFrEF) have reduced quality‐of‐life, repetitive hospital admissions, and …

Mesenchymal stem cell (MSC) transplantation after myocardial infarction (MI) has been
shown to effectively limit the infarct area in numerous clinical and preclinical studies …